Latin American Countries Easing Strict Rules on Product Retesting
This article was originally published in PharmAsia News
Latin American regulators are easing strict local testing requirements for pharmaceuticals, offering a glimmer of hope for multinational companies that are continuously challenged by the time and cost involved in conducting duplicate testing.
You may also be interested in...
The US FDA has added hydroxychloroquine sulfate to the list of drugs outsourcing facilities can compound as pharmacy group calls for more such approvals with COVID-19 driving demand for additional prescription and over-the-counter drugs.
AstraZeneca emptied its warehouses in January. “We said, OK let us pack everything and get it out in the door,” said Tony Mire-Sluis, head of global quality. The firm is allowing only crucial personnel in plants, or those responsible for running a plant or moving products; all others are working from home.
Quality experts with AstraZeneca and Thermo Fisher describe how their companies are responding to the COVID-19 pandemic – but urge industry not to lose focus on monitoring unrelated drug products.